Basics Sarepta Therapeutics, Inc. Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases. IPO Date: July 12, 2012 Sector: Healthcare Industry: Biotech Market Cap: $3.71B Activated in VL: True Average Daily Range Avg Daily Range: $1.57 | 2.41% Avg Daily Range (30 D): $1.48 | 3.09% Avg Daily Range (90 D): $1.92 | 2.83% Institutional Daily Volume Avg Daily Volume: 1.56M Avg Daily Volume (30 D): 4.18M Avg Daily Volume (90 D): 2.53M Trade Size Avg Trade Size (Sh.): 106 Avg Trade Size (Sh.) (30 D): 81 Avg Trade Size (Sh.) (90 D): 71 Institutional Trades Total Inst.Trades: 13,118 Avg Inst. Trade: $4.09M Avg Inst. Trade (30 D): $3.26M Avg Inst. Trade (90 D): $4.4M Avg Inst. Trade Volume: .05M Avg Inst. Trades (Per Day): 4 Market Closing Trades Avg Closing Trade: $8.66M Avg Closing Trade (30 D): $14.3M Avg Closing Trade (90 D): $14.99M Avg Closing Volume: 96.76K     News May 13, 2025 @ 9:37 PM Ten-Year Data From Roche's Breast Cancer Trial Sho... Source: Vandana Singh May 13, 2025 @ 8:14 AM 2 Stocks Near Their 52-Week Lows That Still Aren't... Source: Prosper Junior Bakiny May 5, 2025 @ 5:56 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: N/A May 5, 2025 @ 5:53 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: N/A Apr 3, 2025 @ 7:23 PM Sarepta/Roche Suspend Elevidys Gene Therapy Trials... Source: Vandana Singh Financials   TTM Q1 2025 Q4 2024 Basic EPS $-2.51 $-4.6 $1.67 Diluted EPS $-2.63 $-4.6 $1.56 Revenue $ 2.23B $ 744.86M $ 658.41M Gross Profit $ $ $ Net Income / Loss $ -248.39M $ -447.51M $ 159.05M Operating Income / Loss $ -117.21M $ -300.39M $ 161.68M Cost of Revenue $ $ $ Net Cash Flow $ -186.42M $ -862.14M $ 905.16M PE Ratio     Splits Jul 12, 2012:   1:6